This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ryan, C. J. Articles by Eisenberger, M. Search for Related Content PubMed PubMed Citation Articles by Ryan, C. J. Articles by Eisenberger, M. Social Bookmarking                            What's this?

Chemotherapy for Hormone-Refractory Prostate Cancer: Now It's a Question of "When?"

Charles J. Ryan, Mario Eisenberger

From the Department of Medicine, and UCSF Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA; and the Division of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Address reprint requests to Charles J. Ryan, MD, UCSF Comprehensive Cancer Center, Box 1711, 1600 Divisadero St, San Francisco, CA 94115; e-mail: ryanc{at}medicine.ucsf.edu.

Recently, data from two randomized phase III studies that compared docetaxel-based chemotherapy to mitoxantrone-based therapy demonstrated that treatment with docetaxel can prolong life in a significant way for patients with hormone-refractory prostate cancer. For many patients who experience disease progression after androgen-deprivation therapy, however, chemotherapy may not be immediately indicated. Such cases include those individuals with hormone-refractory disease in the absence of clinical metastases, and those with asymptomatic metastatic disease, for example. As a result, clinicians treating patients with hormone-refractory disease must weigh the benefits of earlier chemotherapy against its risks, and may consider other therapies such as secondary hormonal approaches before initiating chemotherapy. This decision is further complicated by the fact that a phase III study designed to compare secondary hormonal therapy with chemotherapy has failed due to lack of accrual. Furthermore, the limitations of chemotherapy for prostate cancer are being clarified and include a lack of standard second-line therapy as well as uncertain benefits for those with nonmetastatic disease. In this review, we will highlight some of the issues that impact on the decision of when to start chemotherapy and in whom as well as the potential benefits of secondary hormonal approaches.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Kumar, S. Srinivasan, S. Koduru, P. Pahari, J. Rohr, N. Kyprianou, and C. Damodaran Psoralidin, an Herbal Molecule, Inhibits Phosphatidylinositol 3-Kinase-Mediated Akt Signaling in Androgen-Independent Prostate Cancer Cells Cancer Prevention Research, March 1, 2009; 2(3): 234 - 243. [Abstract] [Full Text] [PDF]

				D. R. Berthold, G. R. Pond, R. de Wit, M. Eisenberger, I. F. Tannock, and On behalf of the TAX 327 investigators Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa Ann. Onc., October 1, 2008; 19(10): 1749 - 1753. [Abstract] [Full Text] [PDF]

				K. Fizazi The role of Src in prostate cancer Ann. Onc., November 1, 2007; 18(11): 1765 - 1773. [Abstract] [Full Text] [PDF]

				M. M.R. Bhuiyan, Y. Li, S. Banerjee, F. Ahmed, Z. Wang, S. Ali, and F. H. Sarkar Down-regulation of Androgen Receptor by 3,3'-Diindolylmethane Contributes to Inhibition of Cell Proliferation and Induction of Apoptosis in Both Hormone-Sensitive LNCaP and Insensitive C4-2B Prostate Cancer Cells. Cancer Res., October 15, 2006; 66(20): 10064 - 10072. [Abstract] [Full Text] [PDF]

				E. J. Small and E. A. Klein Challenges and Future Directions in the Prevention and Management of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8143 - 8145. [Full Text] [PDF]